S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

LON:AGYAllergy Therapeutics Share Price, Forecast & News

GBX 14
-0.38 (-2.64 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
13.56
Now: GBX 14
14.30
50-Day Range
11.85
MA: GBX 14.10
15.20
52-Week Range
0.14
Now: GBX 14
15.88
Volume120,309 shs
Average Volume167,682 shs
Market Capitalization£89.22 million
P/E Ratio11.67
Dividend YieldN/A
BetaN/A
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.
Read More
Allergy Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.89 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1903-844700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£77.48 million
Cash FlowGBX 5.99 per share
Book ValueGBX 8 per share

Profitability

Miscellaneous

Employees500
Market Cap£89.22 million
Next Earnings Date9/23/2020 (Estimated)
OptionableNot Optionable
GBX 14
-0.38 (-2.64 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allergy Therapeutics (LON:AGY) Frequently Asked Questions

How has Allergy Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Allergy Therapeutics' stock was trading at GBX 9.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGY shares have increased by 51.4% and is now trading at GBX 14.
View which stocks have been most impacted by COVID-19
.

When is Allergy Therapeutics' next earnings date?

Allergy Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, September 23rd 2020.
View our earnings forecast for Allergy Therapeutics
.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) posted its quarterly earnings data on Wednesday, March, 4th. The company reported $2.40 earnings per share (EPS) for the quarter.
View Allergy Therapeutics' earnings history
.

Has Allergy Therapeutics been receiving favorable news coverage?

Media headlines about AGY stock have been trending negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergy Therapeutics earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Allergy Therapeutics
.

Who are some of Allergy Therapeutics' key competitors?

What other stocks do shareholders of Allergy Therapeutics own?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the following people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 55)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 14.

How big of a company is Allergy Therapeutics?

Allergy Therapeutics has a market capitalization of £89.22 million and generates £77.48 million in revenue each year. Allergy Therapeutics employs 500 workers across the globe.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is www.allergytherapeutics.com.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.